Dr Jackie Hunter to become CEO of BBSRC

Will take up the post on 21 October

Dr Jackie Hunter has been named as the new Chief Executive and Deputy Chair of the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).

Hunter is currently Chief Executive of OI Pharma Partners. From 1989–2010 she worked for GlaxoSmithKline and its predecessor companies and was at Astra (now AstraZeneca) earlier in her career. She was made CBE in 2010 for services to the pharmaceutical industry.

‘The BBSRC plays a vital role in shaping and underpinning the diverse and exciting science base that is essential to maintain the international reputation of UK bioscience and biotechnology,’ said Hunter. ‘The potential of this research, and the BBSRC investments in innovation, to support the UK’s growing bioeconomy and socio-economic challenges is huge. I am looking forward to working with the wealth of talent within BBSRC, the research community and its many partner organisations to drive forward UK bioscience.’

The appointment is for four years. Hunter will succeed Professor Douglas Kell.

You may also like

Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Manufacturing

Naobios and Sumagen sign exclusive partnership to develop HIV vaccine

Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Regulatory

4SC AG receive Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Research & Development

Serum Institute of India collaborates with Univercells to enhance availability of affordable personalised oncology

The partnership endeavours to speed up development times and distribute personalised cancer vaccines to all locations globally, rather than just economically developed countries
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Research & Development

Exeliom Biosciences announces three Phase II immuno-oncology clinical trials

Phase II clinical trials will investigate efficacy of lead candidate EXL01 – in gastric cancer with GERCOR, in NSCLC with CHU Lille and in hepatocellular carcinoma with Centre Eugène Marquis of Rennes
Subscribe now